During our initial grant period, we were extremely productive in terms of recruitment, retention, scientific output, and training future scholars. RADAR recruited over 1,200 study participants and maintained a 80% retention rate since it was launched. To date, more than 40 scientific publications have been published. RADAR also served as a platform for innovative research, with more than 25 connected studies and seven concepts via the NIDA C3PNO consortium.
The project utilizes a multilevel research design that incorporates biological, dyadic, and network components to provide an unprecedented view into HIV transmission epidemiology. Cohort members are assessed every six months on individual behavior and risk; relationship and sexual partner characteristics; and social, sexual, and drug-using networks. Members also receive multiple biological assessments (drug and STI testing and banking of plasma and DNA) at each six-month assessment. The RADAR cohort includes both HIV-positive and -negative participants, and it continues to build a repository of HIV sequence data and biospecimens from time points before, during, and after acute infection that can facilitate future proposals evaluating substance use, HIV risk, pathogenicity, and immunity.
Learn More About RADAR
RADAR is the largest longitudinal study of YMSM ever conducted and is unique in its focus of this young risk group, its diversity (33.7% Black, 29.9% Latino/Hispanic, 25.5% White, 7.6% multi-racial, 2.4% Asian, < 1% Other, Pacific Islander/Native American/Native Alaskan).
This mirrors the demographics of the city of Chicago, which is also the urban epicenter of HIV and drug epidemics in the Midwest (Cook County, IL, where Chicago is located, was fourth in HIV incidence in 2017).
Geographic Reach and Study Milestones
- Study participants reside in over 40 US states and 6 countries.
- RADAR has provided over 6,000 HIV tests to study participants.
- RADAR was the first major study to enroll dyads into a YMSM cohort.
- RADAR has successfully retained cohort participants who are living with HIV and who are HIV-negative (>80%).
- RADAR researchers publish scientific outputs frequently (40+ publications).
- RADAR created an innovative research platform (25+ connected studies; 7 concepts via NIDA C3PNO consortium).
- Keep a pulse on emerging trends in drug use, HIV risk/preventive behaviors, and care continuum engagement
- Continue to enroll cohort members’ new serious partners
- Build on our provocative findings of high levels of systematic inflammation in the RADAR cohort regardless of HIV status
- Continue to add specimens and data to our well-characterized biobehavioral respository to provide a platform for high-impact science
A Community-Embedded Study
The RADAR Community Advisory Board (CAB)
- Principal Investigator: Dr. Brian Mustanski
- Co-Investigators: Dr. Richard D’Aquila, Dr. Patrick Janulis, Dr. Thomas McDade, Dr. Michael Newcomb, Dr. Sanjiv Shah, Dr. Harry Taylor
- Consultant: Dr. Adam Carrico
- Funder: National Institute on Drug Abuse